Johnson & Johnson
2016 sales: $1.035 billion
Tracleer, which the FDA approved back in 2001, may be an elderly product, but it’s still pulling in big bucks. In 2016, the sales of the med—the first oral treatment approved to treat pulmonary arterial hypertension, according to developer Actelion—declined by 18% at constant exchange rates, but Tracleer still passed the blockbuster barrier.
Those sales contributed to a portfolio of products that last year spurred Johnson & Johnson to pursue a buyout of the Swiss drugmaker. And while Actelion initially held out and later flirted with Sanofi, it ultimately came back to strike a multipronged, $30 billion deal that sent Tracleer and its marketed peers to New Jersey.
Tracleer’s new owner, meanwhile, is still reaping benefits despite Tracleer’s demise. The med came along with next-gen PAH therapy Opsumit, a fellow oral contender whose sales are on the rise.
Outside of PAH, Tracleer bears EU approvals for reducing the number of new digital ulcers in patients grappling with systemic sclerosis and ongoing digital ulcer disease.